Home > Financial Ratios > MANKIND PHARMA

MANKIND PHARMA
EV/Core EBITDA

    Back to All Ratios
MANKIND PHARMA is part of below Screeners ↓
Top Large Cap Stocks with Best Fundamentals
COMMUNITY POLL
for MANKIND PHARMA
Please provide your vote to see the results

MANKIND PHARMA Last 5 Year EV/Core EBITDA History

[Consolidated]

Mar2024Mar2023Mar2022Mar2021Mar2020
   EV/Core EBITDA(x) 32.31-0.120.23-0.23-0.16

What is the latest EV/Core EBITDA ratio of MANKIND PHARMA ?

The latest EV/Core EBITDA ratio of MANKIND PHARMA is 32.31 based on Mar2024 Consolidated results.
Year EV/Core EBITDA
Mar202432.31
Mar2023-0.12
Mar20220.23
Mar2021-0.23
Mar2020-0.16

How is EV/Core EBITDA of MANKIND PHARMA Trending?

Years EV/Core EBITDA % Change
Mar2024 32.31
Positive
Mar2023 -0.12
Negative
Mar2022 0.23
Positive
Mar2021 -0.23
Negative
Mar2020 -0.16 -

Other Financial Ratios of MANKIND PHARMA


Compare EV/Core EBITDA ratio of peers of MANKIND PHARMA

Peers & Returns Market Capitalization 1 Week 1 Month 1 Year
MANKIND PHARMA ₹99,979.2 Cr 2.1% 3.7% 9.5% Stock Analytics
SUN PHARMACEUTICAL INDUSTRIES ₹416,393.0 Cr -2.8% 7.6% 8.4% Stock Analytics
DIVIS LABORATORIES ₹153,258.0 Cr -2.3% 0.8% 72.7% Stock Analytics
CIPLA ₹116,434.0 Cr -5.4% -1.5% 0.8% Stock Analytics
TORRENT PHARMACEUTICALS ₹109,474.0 Cr -0.8% 6.8% 25.6% Stock Analytics
DR REDDYS LABORATORIES ₹95,465.9 Cr -5.5% 1.6% -5.1% Stock Analytics


MANKIND PHARMA Share Price vs Sensex


Share Price Returns(%) 1 Week 1 Month 1 Year
MANKIND PHARMA

2.1%

3.7%

9.5%

SENSEX

0.7%

4%

6.3%


You may also like the below Video Courses